Risperidone ER is a Small Molecule owned by Indivior, and is involved in 7 clinical trials, which were completed.

Risperidone (RBP-7000) elicits antipsychotic activity by antagonizing serotonin 5-HT2A and dopamine D2 receptors. The drug candidate by blocking the dopaminergic D2 receptors in the limbic system alleviates positive symptoms of schizophrenia. By blocking the serotonin 5-HT2A receptor, it leads to an increase in dopamine transmission and thus eliminates the core negative symptoms.

The revenue for Risperidone ER is expected to reach a total of $2.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Risperidone ER NPV Report.

Risperidone ER is currently owned by Indivior.

Risperidone ER Overview

Risperidone (Perseris) is a benzisoxazole derivative, acts as an atypical anti-psychotic agent. It is formulated as extended release powder for suspension for subcutaneous route of administration. Perseris is indicated for the treatment of schizophrenia in adults.

Indivior Overview

Indivior develops and markets medicines for the treatment of opioid addiction. The company offers suboxone a monthly depot, and only approved film treatment for opioid dependence; subutex, a mono-buprenorphine sublingual tablet, sublocad injection, and nalscue for opioid use disorder; and perseris for schizophrenia. Its pipeline portfolio encompasses buprenorphine-based products, including INDV-1000 in pre-clinical phase and INDV-2000 in Phase I for substance use disorder; and AEF0117 in Phase II for treatment of cannabis disorder. Indivior offers products in the form of film, tablets, and subutex tabs. It offers its products in the US, Australia, Malaysia, France, Italy, Spain, Germany, Canada, and the UK. Indivior is headquartered in Slough, the UK.

The company reported revenues of (US Dollars) US$791 million for the fiscal year ended December 2021 (FY2021), an increase of 22.3% over FY2020. The operating profit of the company was US$204 million in FY2021, compared to an operating loss of US$163 million in FY2020. The net profit of the company was US$205 million in FY2021, compared to a net loss of US$148 million in FY2020. The company reported revenues of US$232 million for the third quarter ended September 2022, an increase of 5% over the previous quarter.

Quick View – Risperidone ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Risperidone ER
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.